SAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating Sage Therapeutics, Inc. on Behalf of Sage Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 08/22/23
SAGE INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the FirmPRNewsWire • 08/19/23
SAGE INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the FirmBusiness Wire • 08/15/23
Why Sage Lost Half Its Value After The FDA Approved Its Depression DrugInvestors Business Daily • 08/07/23
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/07/23
Sage Therapeutics' stock craters 49% after FDA approves zuranolone for postpartum depression, but not major depressive disorderMarket Watch • 08/07/23
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business ProgressBusiness Wire • 08/07/23
Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023Business Wire • 08/05/23
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive DisorderBusiness Wire • 08/05/23
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 08/03/23